ACET Stock Forecast & Price Target

Adicet Bio is viewed positively because prula-cel has shown compelling early clinical efficacy in heavily pretreated lupus nephritis and SLE, with 50% complete renal response at 12 months, 54% DORIS remission, and durable ongoing responses through 12 to 21 months. Its safety profile also stands out, with no CRS above Grade 2, no ICANS, no IEC-HS, and only 8.3% Grade 3 or higher infections, while all patients discontinued background immunosuppressants and most tapered steroids. The outlook is further supported by FDA-aligned pivotal study start-up next quarter, a planned double-digit enrollment trial, and the potential to expand into a roughly 70,000-patient U.S. non-renal SLE market, alongside near-term catalysts in 1H:27 and mid-2027.

Adicet Bio is a clinical-stage biotechnology company facing substantial downside risk because its lead programs remain exposed to negative clinical data, safety signals, slower development, and regulatory failure. The outlook is further pressured by an inability to achieve sales estimates and by commercial competition from current and future therapies, which could prevent ADI-001 from proving efficacious or gaining meaningful traction. Even with a DCF framework using a 50% probability of approval, 11% discount rate, and 1.5% terminal growth rate, the projected $375M total market value implies material execution risk and potential medium- to long-term equity dilution.